Focused On-demand Library for Nuclear factor 1 X-type

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q14938

UPID:

NFIX_HUMAN

Alternative names:

CCAAT-box-binding transcription factor; Nuclear factor I/X; TGGCA-binding protein

Alternative UPACC:

Q14938; B4DM25; O60413; Q0VG09; Q12859; Q13050; Q13052; Q5U094; Q9UPH1; Q9Y6R8

Background:

Nuclear factor 1 X-type, also known as CCAAT-box-binding transcription factor or TGGCA-binding protein, plays a pivotal role in cellular and viral promoter activation and adenovirus replication. It specifically recognizes and binds the palindromic sequence 5'-TTGGCNNNNNGCCAA-3', showcasing its critical function in transcription and replication processes.

Therapeutic significance:

Linked to Malan syndrome and Marshall-Smith syndrome, Nuclear factor 1 X-type's genetic variants underscore its clinical relevance. Understanding the role of Nuclear factor 1 X-type could open doors to potential therapeutic strategies for these genetic disorders, highlighting the importance of targeted research in uncovering novel treatment avenues.